


























































Curcumin Conjugates of Non-steroidal Anti-Inflammatory
Drugs: Synthesis, Structures, Anti-proliferative Assays,
Computational Docking, and Inflammatory Response
Kenneth K. Laali,*[a] Angela T. Zwarycz,[a] Nicholas Beck,[a] Gabriela L. Borosky,[b]
Manabu Nukaya,[c] and Gregory D. Kennedy[c]
In an effort to combine the anti-proliferative effect of CUR-BF2
and CUR compounds with anti-inflammatory benefits of non-
steroidal anti-inflammatory drugs (NSAIDs), a library of the bis-
and mono-NSAID/CUR-BF2 and NSAID/CUR conjugates were
synthesized by coupling flufenamic acid, flurbiprofen, naproxen,
indomethacin, and ibuprofen to diversely substituted hydroxy-
benzaldehydes via an ester linkage, and by subsequent reaction
with acetylacetone-BF2 to form the bis- and the mono-NSAID/
CUR-BF2 adducts. Since conversion to NSAID/CUR by the
previously developed decomplexation protocol showed limited
success, a set of NSAID/CUR conjugates were independently
prepared by directly coupling the NSAIDs with parent curcumin.
The bis-NSAID/CUR-BF2 and bis-NSAID-CUR hybrids exhibited
low cytotoxicity in NCI-60 assay, and in independent cell
viability assay on colorectal cancer (CRC) cells (HCT116, HT29,
DLD-1, RKO, SW837, CaCo2) and in normal CR cells
(CCD841CoN). By contrast, the mono-naproxin and mono-
flurbiprofen CUR-BF2 adducts exhibited remarkable anti-prolifer-
ative and apoptopic activity in NCI-60 assay most notably
against HCT-116 (colon), OVCAR-3 (ovarian), and ACHN (renal)
cells. Computational molecular docking calculations showed
favorable binding energies to HER2, VEGFR2, BRAF, and Bcl-2 as
well as to COX-1 and COX-2, which in several cases exceeded
known inhibitors. The main interactions between the ligands
and the proteins were hydrophobic, although several hydrogen
bonds were also observed. A sub-set of six compounds that had
exhibited little or no cytotoxicity were tested for their anti-
inflammatory response with THP-1 human macrophages in
comparison to parent NSAIDs or parent curcumin.
1. Introduction
Whereas potential health benefits of parent curcumin and its
anticancer, anti-inflammatory, antioxidant, and anti-mutagenic
effects have been extensively studied,[1–5] its complex signaling
pathways and biological profile, coupled to poor pharmacoki-
netic properties have been major obstacles in developing a
CUR-based anti-cancer drug, despite much effort to devise
delivery methods by nanotechnology formulation or encapsula-
tion into liposomes, or by inclusion into water soluble host
molecules such as β-cyclodextrin.[6–8]
Much work has been devoted to improving solubility,
metabolic stability, lipophilicity, and other properties through
synthesis of analogs, and these developments have been
summarized in recent reviews.[9,10] Work from this laboratory has
focused on structural modifications by tuning steric and
electronic effects through introduction of activating and
deactivating substitutents, introducing fluorinated moieties in
an effort to improve lipophilicity and metabolic stability, syn-
thesis of pyazole and isoxazole derivatives, and synthesis of
libraries of CUR-inspired heterocyclic analogs.[11–14] Libraries of
deuterated-CUR-BF2 and CUR analogs were also synthesized
and studied.[15] These strategies produced diverse libraries of
“CUR-inspired” compounds, and in-vitro bioassay studies identi-
fied several potential “hit compounds” with high anti-prolifer-
ative and apoptotic efficacy, most notably in multiple myeloma
and colorectal cancer (CRC) that warrant further studies. The
CUR-BF2 adducts of some of these compounds proved
especially effective. Other laboratories have found new applica-
tions for some CUR-BF2 analogs as fluorescence imaging probes
for detecting amyloids, and half-CUR-BF2 compounds as PET
imaging probes.[16] Taking into account the connection between
inflammatory response and development of cancer,[17] synthesis
of hybrid compounds that could combine the anti-cancer
properties of a pro-drug with the anti-inflammatory response of
an NSAID is a desirable goal. We know of only two published
studies on CUR/NSAIDs.[18,19] with one study reporting inhibitory
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effect on proliferation of RAW 264.5 cell line.[18] The reported
IC50 values showed low cytotoxicity for most, except for a
mono-NSAID/CUR adduct employing flufenamic acid and a bis-
NSAID/CUR adduct with salicylic acid. A salicylic acid mono-
adduct, and a salalate bis-adduct showed notable anti-inflam-
matory effect against RAW 264.4 cell line. The other study
reported spectroscopic and computational study on the mono-
ibuprofen/CUR compound.[19]
CUR has recently been classified as both a PAINS (pan-assay
interference compounds) and an IMPS (invalid/improbable
metabolic panaceas) candidate.[20,21] In view of the ongoing
active debate in the medicinal chemistry community concern-
ing the therapeutic efficacy of parent curcumin,[20–22] a continu-
ing search for CUR-inspired compounds that could overcome
these drug-discovery challenges appears worthy.
The present study reports on (1) synthesis of a diverse set of
bis-NSAID/CUR-BF2, bis-NSAID/CUR, and mono-NSAID/CUR com-
pounds, (2) computational docking studies to determine bind-
ing energies to HER2, VEGFR2, BRAF, Bcl-2, COX-1, and COX-2,
(3) anti-proliferative activity as compared to CUR-BF2 and CUR
compounds in in-vitro bioassay against a panel of 60 cancer cell
lines, and more specifically in human CRC cells (HCT116, HT29,
DLD-1, RKO, SW837, and Caco2), and (4) comparative anti-
inflammatory assay for a subset of flufenamic acid, indometha-
cin, and ibuprofen conjugates with THP-1 human macrophages
in comparison to the parent NSAIDs and parent curcumin.
Several factors were considered in the selection of the NSAIDS
in this study: flufenamic acid and flurbiprofen were chosen
because of the presence of fluorines, well known to increase
lipophilicity and metabolic stability, with the added benefit of
19F NMR as a diagnostic tool to monitor reaction progress and
to confirm structural integrity of the synthesized hybrid
compounds. Selection of naproxen and ibuprofen stemmed
from their wide use as over the counter drugs, and indometha-
cin because of its efficacy in pancreatic cancer by down-
regulating of COX-2.[23]
2. Results and Discussion
Variously substituted hydroxybenzaldehydes were coupled to
flufenamic acid, flurbiprofen, indomethacin, naproxen, and
ibuprofen using classical Steglich esterification protocol, em-
ploying DCC/DMAP, and the coupling adducts were obtained in
good to excellent isolated yields. These were then reacted with
acetylacetone-BF2 complex (Scheme 1) in 2 :1 ratio, following
previously established procedures,[11–15] to obtain the corre-
sponding bis-NSAID/CUR-BF2 adducts. Thermal decomplexation
of the BF2 adducts in the Monowave reactor
[24] were successful
in some cases depending on the NSAID, and from this simple
route the corresponding bis-NSAID/CUR compounds were
directly obtained (Scheme 1).
By using a different strategy (Scheme 2) a library of bis-
NSAID/CUR and mono-NSAID/CUR conjugates were synthesized,
from which the corresponding CUR-BF2 adducts were obtained
by reaction with BF3.
[25]
Collectively these efforts led to the synthesis and isolation
of libraries of hybrid compounds shown in Figures 1–2.
Octanol/water partition coefficients (LogP) are displayed below
each structure. LogP is a measure of lipophilicity, useful in
estimating the distribution of drugs within the body. Hydro-
phobic compounds with high logP values are mainly distributed
into hydrophobic regions such as lipid bilayers, while hydro-
philic molecules (low logP values) are primarily found in blood
serum.
2.1. Structural Studies
Since efforts to grow crystals suitable for X-ray analysis were
unsuccessful, the geometries of the compounds were optimized
by density functional theory (DFT) computations at the B3LYP/
6-31G* level. Some representative analogs are shown in Fig-
ure S1. The planar bis-α,β-unsaturated-β-diketone backbone
Scheme 1. General procedure for the synthesis of symmetrical bis-NSAID/CUR-BF2 -> bis-NSAID/CUR. R
1/R2=3,5-dimethoxy and 2,6-dimethoxy;






























































converged to the enolic tautomer, and the CUR-BF2 adducts
presented a symmetrically BF2-coordinated structure.
2.1.1. In-vitro Bioassay
The bis-NSAID/CUR-BF2 and their corresponding CUR adducts
proved to have little or no cytotoxicity by the NCI-60 assay (SI
file and experimental section). Similar results were also
observed in independent cell viability assay on colorectal cancer
(CRC) cells (HCT116, HT29, DLD-1, RKO, SW837, CaCo2) and in
normal CR cells (CCD841CoN) (Figure S2). By contrast the mono-
NSAID/CUR-BF2 compounds proved to be highly active, with
mono-flurbiprofen/CUR-BF2 8 and mono-naproxin/CUR-BF2 10
exhibiting remarkable inhibitory effect on proliferation and
apoptosis (mean values 20.3 and 36.6 respectively), in particular
for colon, ovarian, and renal cancer cells (Tables S14 and S11),
while the mono-flufenamic acid/CUR-BF2 adduct 5 was less
potent (mean value 81). Removal of the BF2 results in significant
loss of activity with the mean values for the mono-naproxin/
CUR 20 and mono-ibuprofen/CUR 21 dropping to 89.8 and 87.9
respectively, and with mono-flufenamtic acid/CUR adduct 16
displaying essentially no cytotoxicity. Compounds 8 and 10
were then subjected to the five-dose screening assay by the
NCI at concentrations 10@5 to 10@8 molar. Whereas compound
10 retained anti-proliferative activity at 10@6 molar, notably
toward leukemia (RPMI 8226), colon (HCT-116), CNS (U-251),
and ovarian (OVAR-8) cancer cells (Table S14b), compound 8
lost significant anti-proliferative activity at 10@6 molar concen-
tration.
2.1.2. Stability in plasma and in solvent
Since one of the important functions of the proteins in human
plasma is to transport drugs, in a test experiment the bis-NSAID/
CUR-BF2 compound 1 was allowed to incubate with citrated human
plasma in water/DMSO (see experimental) at 37 °C with 5% CO2 for
8 hours. The 19F and 1H NMR spectra (and relative integrals) of the
recovered material showed that circa 90% of the compound had
remained structurally intact, implying that the release of NSAID is
not a major contributor to the observed bioactivity. Furthermore,
the NMR samples of NSAID/CUR-BF2 and NSAID/CUR compounds
remained unchanged when stored at r.t. for days.
































































Molecular docking calculations for model compounds were
performed with the aim to elucidate the factors determining
the bioactivity of the hybrid compounds. Binding energies in
the active site of various proteins involved in carcinogenic
processes were determined and compared with the binding
affinities of their corresponding known inhibitors applied in
anticancer therapies. The proteins selected for these docking
studies are involved in diverse oncogenic pathways, which were
described in previous works.[11–14] In addition, the potential anti-
inflammatory activity of the CUR-NSAID conjugates was
evaluated by docking calculations in the active site of cyclo-
oxygenase enzymes COX-1 and COX-2. These enzymes are
responsible for inflammatory processes, and their pharmacolog-
ical inhibition can relieve the symptoms of inflammation and
pain.[26,27] Moreover, the expression of COX-2 was found to be
increased in a variety of malignancies including pancreatic
cancer, and COX-2-mediated synthesis of prostaglandins favors
the growth of tumor cells by stimulating proliferation and
angiogenesis.[28]
In general, the studied curcuminoids yielded very good
binding energies that were similar to, and in several cases more
favorable than, the usually employed chemotherapeutic inhib-
itors (Tables S1 and S2). The main interactions between the
ligands and the proteins were hydrophobic, although some
hydrogen bonds were also observed (Figures 3 and 4). It should
be noted that in COX-1 the binding mode of the conjugates






























































were different from that of the NSAIDs. In COX-2, the studied
compounds docked into the same site as meloxicam and
indomethacin.
Among the NSAID/CUR-BF2 and NSAID-CUR conjugates that
showed significant binding affinities with cyclooxygenases,
most presented greater inhibitory action against the inducible
isoform COX-2 (Table S16) which is implicated in the inflamma-
tory response, than against the constitutive form of this enzyme
(COX-1), inhibition of which is associated with gastric, renal and
other adverse effects, such as inhibition of platelet
aggregation.[29] These observations appear promising for the
development of new anti-inflammatory agents with an im-
proved tolerability profile. Nevertheless, although favorable
docking is a necessary requirement for bioactivity, processes
that occur prior to ligand-protein interaction, such as solubility,
absorption, transport, metabolism, and membrane permeability,
can affect the observed in vitro and in vivo activities.































































Lack of cytotoxicity in the bis-NSAID-CUR-BF2 adducts prompted
a preliminary investigation into their anti-inflammatory effect. A
comparative anti-inflammatory assay using IL-1β, a pre-inflam-
matory cytokine, with THP-1 human macrophage cell line on a
sub-set of six NSAIDS-CUR compounds showed better anti-
inflammatory response (suppression of LPS-induced IL-1β
expression) compared to parent curcumin (Figure 3). The
flufenamic acid/CUR conjugate induced better suppression of
LPS-induced inflammatory response than the parent flufena-
mate acid (Figure 5), while the anti-inflammatory response by
ibuprofen/CUR and flurbiprofen/CUR conjugates was not sig-
nificantly improved compared to the respective parent NSAIDS.
It has been reported that fenamate NSAIDs (e.g., flufenamic
acid, meclofenamic acid, and metenamic acid) suppressed the
release and production of IL-1β in mouse bone marrow-derived
macrophages (BMDMs) via inhibition of NLRP3 inflammasome
which is one of the most well-characterized inflammasome
pathways.[30] By contrast, ibuprofen hardly inhibited the release
and production of IL-1β and NLRP3 inflammasome pathway in
BMDMs.[30] Interestingly, parent curcumin also suppressed the
release and production of IL-1β through the inhibition of
NLRP3 inflammasome in BMDMs.[31] Therefore, we surmise that
flufenamic acid/CUR conjugates may act as selective and
synergistic NLRP3 inflammasome inhibitors.
3. Summary
A series of the bis- and the mono-NSAID/CUR-BF2 and NSAID-
CUR hybrids were synthesized and characterized. Whereas the
bis-adducts exhibited little or no cytotoxicity in in-vitro bioassay,
the mono-NSAID-CUR-BF2 compounds, in particular the naprox-
en and flurbiprofen conjugates 8 and 10, proved to be highly
potent. Removal of the BF2 group, as in the mono-naproxin/
Figure 3. 2D representation of the most favorable binding pose of the mono-NSAID-CUR 8 in the active site of COX-2. The hydrophobic interactions between






























































CUR 20 and mono-ibuprofen/CUR 21 resulted in significant loss
of activity. Computational molecular docking calculations
showed favorable binding energies to HER2, VEGFR2, BRAF, and
Bcl-2 as well as to COX-2. Finally, we found that the CUR-
conjugated flufenamic acid compounds showed better anti-
inflammatory response relative to parent flufenamaic acid,
parent curcumin, and other NSAIDs (ibuprofen, flurbiprofen).
Present studies suggest that fenamate NSAIDs/CUR conjugates
could become effective and selective drug candidates for
several inflammatory diseases implicated in IL-1β and NLRP3
inflammasome.[32]
It is worth noting that some of the new molecules show
promising activity toward multiple targets. The multitarget
approach of drug discovery has several advantages (lower dose
requirement, less side effects, reduced pharmaceutical pollu-
tion, etc.), especially in treating complex diseases.
Experimental Section
General – The NSAIDs, substituted hydroxyl-benzaldehydes, DCC
and DMAP were all high purity commercially available samples and
were used without further purification. NMR spectra were recorded
on a 500 MHz instrument using CDCl3, DMSO-d6 or acetone-d6 as
solvent. 19F NMR were referenced relative to external CFCl3. HRMS
analyses were performed on a Finnigan Quantum ultra-AM in
electrospray mode using methanol as solvent. Decomplexation of
CUR-BF2 adducts to CUR was effected by using a benchtop
Monowave reactor (Anton Paar). FT-IR spectra were recorded in ATR
mode (as thin films formed via DCM evaporation). Melting points
were measured in open capillaries and are not corrected.
Synthesis of NSAID-Aldehyde Adducts- The selected hydroxy-
benzaldehyde was added to a round bottom flask and dissolved in
a minimal amount of chloroform. The NSAID (1.5 mmol), DCC
(1.6 mmol), and DMAP (1.6 mmol) were subsequently added and
the reaction mixture was flushed with nitrogen and allowed to stir
at room temperature overnight. Upon completion (monitored by
TLC) it was transferred to a freezer to allow the dicyclohexylurea
(DCU) side product to fall out of solution. The reaction mixture was
then quickly filtered through a Buchner funnel and the filtrate was
transferred to a small beaker, washed with a 5% HCl solution (3×
10 mL) and extracted with chloroform. The organic layer was dried
(sodium sulfate), filtered, and the solvent was evaporated under
vacuum to give the crude product as an oil, which was purified by
crystallization from isopropanol followed by vacuum drying.
Synthesis of bis-NSAID-CUR-BF2 Adducts (Method 1) – To the
NSAID-aldehyde adduct (0.55 mmol) charged into a multi-neck
round bottom flask, was added acetylacetone-BF2 adduct
(0.25 mmol) and the mixture was dissolved in a minimal amount of
ethyl acetate and flushed with nitrogen. Then n-butylamine
(0.055 mmol) was introduced dropwise under stirring and the
reaction was allowed to continue overnight, whereupon a solid
precipitate was formed. When the spot due to NSAID-aldehyde
adduct was no longer detectable by TLC, the reaction mixture was
cooled to 0 °C and the solid product was filtered through a Buchner
funnel, washed with cold ethyl acetate and dried under vacuum.
Synthesis of bis-NSAID-CUR Adducts (Method 1) – The bis-NSAID-
CUR-BF2 adduct synthesized via method 1 (0.1 mmol) was mixed
with sodium oxalate (0.2 mmol) and charged into a Monowave
reactor[21] vial equipped with a stir bar. Then 6 mL of 8 :2 methanol/
water was added and the tube was sealed and heated to 140 °C for
6 minutes in the Monowave reactor. After cooling, the product was
filtered, washed with water, and dried under vacuum.
Synthesis of bis- and mono-NSAID-CUR Adducts (Method 2) –
synthetic curcumin (0.5 mmol), DCC (0.55 mmol), DMAP
(0.05 mmol) and the NSAID (1.05 mmol for bis-adduct and
Figure 4. 3D representation of the most favorable binding mode of
compound 8 in the active site of COX-2. Hydrogen-bond interactions are
depicted as green lines.
Figure 5. Inflammation Assay. THP-1 cells were treated with LPS (100 ng/ml)
for two hours. After the induction of inflammatory response by LPS
treatment, cells were treated with DMSO or CUR compounds (10 μM) for
24 hours. The IL-1β expression levels were normalized using the β-actin
gene expression. Error bars represent SEM. Each groups contained more
than two samples. *significantly different relative to LPS-treated controls
(p <0.05), ** significantly different relative to LPS/flufenamic acid-treated
samples. Abbreviations: FFL: flufenamic acid; IBP: ibuprofen; FLB: flurbipro-
fen; M-FFL: compound 16; M-IBP: compound 21; DM4IBP-BF: compound 12;































































0.45 mmol for the mono-adduct) were added to a round bottom
flask and dissolved in DCM (15 mL). The mixture was stirred and the
reaction was allowed to continue for 24 hours. TLC analysis of the
crude reaction mixture showed the formation of both mono-, and
bis-adducts (irrespective of molar equivalence of NSAID) along with
unreacted curcumin. The crude mixture was washed with saturated
NaHCO3 solution, and the DCM layer was separated. The products
were separated by column chromatography using hexane/ethyl
acetate (40%). Fractions containing the respective products were
combined and the solvent was removed leaving behind an oil,
which was crystallized by dissolving in DCM and adding hexane,
followed by filtration and vacuum drying.
Synthesis of bis- and mono-NSAID-CUR-BF2 Adducts (Method 2) –
To a multi-neck round bottom flask, 0.05 mmol of either the bis- or
the mono-NSAID-CUR conjugate synthesized via method 2 was
added and was dissolved in dry DCM. The solution was flushed
with nitrogen with efficient stirring, then 0.075 mmol of BF3 (as a
solution of 48% BF3-etherate) diluted in 0.5 mL of dry DCM was
added dropwise into the flask via a syringe through a septum, and
the reaction was allowed to stir at r.t. for circa 2 hours (completion
was checked by TLC). The solvent was evaporated and the product
was washed with diethyl ether, filtered, and dried under vacuum.
Stability Tests in Human Plasma and in Solvent
Compound 1 (20 mg) was dissolved in DMSO and allowed to mix
with citrated human plasma (sigma-Aldrich) (1 mL) in a 24-well
plate and incubated at 37 °C with 5% CO2 for 8 hours. The resulting
mixture was freeze-dried, extracted with acetone-d6 and directly
checked by 19F and 1H NMR.
NMR samples of the bis- and the mono-NSAID/CUR-BF2 adducts in
acetone-d6 or DMSO-d6 and those of the bis- and mono-NSAID/CUR
adducts dissolved in CDCl3 showed minimal decomposition (<5%)
by NMR when kept at r.t. overnight or stored in refrigerator for
several days.
bis-Flufenamic acid/CUR-BF2 Adduct (1): Yield 55%, off-white solid,
mp 240–242 °C, Rf 0.70 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 9.43 (s, 2H), 8.28 (dd, J=1.5 and 8.0 Hz, 2H), 8.08 (d,
16.0 Hz, 2H), 7.65–7.57 (unresolved m, 8H), 7.45–7.41 (unresolved
m, 4H), 7.36 (s, 4H), 7.23 (d, J=15.5 Hz, 2H), 7.01 (pseudo-dt, J=1.0
and 8.5 Hz, 2H), 6.54 (s, 1H), 3.94 (s, 12H). 19F NMR (acetone-d6,
470 MHz): δ @63.30 (6F, CF3), @140.25 (s, 11B@F), @140.18 (s, 10B@F).
13C NMR (acetone-d6, 125 MHz): δ 180.6, 165.4, 153.1, 147.0, 146.9,
146.5, 141.7, 141.6, 135.3, 133.0, 132.4, 131.4, 131.2, 130.4, 124.8,
121.8, 119.6 (q, JCF=3.9), 118.8, 117.7 (q, JCF=3.8), 114.7, 112.0,
106.2, 102.1, 55.9. IR (cm@1): 2941, 1705, 1620, 1593, 1557, 1501,
1456, 1423, 1331, 1256, 1207, 1130, 1047.
bis-Flufenamic acid/CUR Adduct (14): Yield 96%, Yellow solid, mp
209 °C, Rf 0.62 (40% EtOAc in hexane). 1H NMR (CDCl3, 500 MHz): δ
9.50 (s, 2H), 8.32 (d, J=7.7 and 2.0 Hz, 2H), 7.65 (d, J=16.5 Hz, 2H),
7.50–7.30 (unresolved m, 14 H!), 6.93–6.90 (unresolved m, 2H), 6.88
(s, 4H), 6.61 (d, J=15.5 Hz, 2H), 5.93 (s, 1H), 3.89 (s, 12H). 19F NMR
(CDCl3, 470 MHz): δ @62.87. 13C NMR (CDCl3, 125 MHz): δ 183.1,
166.3, 152.8, 147.3, 141.4, 140.4, 135.0, 133.6, 132.8, 131.8 (q, J=
32.4 Hz), 130.1, 129.9, 124.5, 124.4, 123.9 (q, J=271.8 Hz), 119.7 (q,
J=3.8), 118.5, 118.0 (q, J=3.9), 114.2, 111.7, 104.8, 101.8, 56.3.
HRMS (ESI): m/z [M+H]+ calcd for C51H41F6N2O10: 955.26654; found:
955.2612. IR (cm@1): 3331, 2961–2843, 1701, 1595, 1506, 1456, 1418,
1333, 1254, 1206, 1130, 1040.
bis-Flufenamic acid/CUR-BF2 Adduct (2): Yield 67%, red solid, mp
273 °C, Rf 0.61 (40% EtOAc in hexane). 1H NMR (DMSO-d6,
500 MHz): δ 9.24 (br s, NH), 8.28 (d, J=16.0 Hz, 2H), 8.17 (dd, J=8.2,
2.0 Hz, 2H), 7.61–7.54 (m, 9H), 7.38–7.34 (m, 6H), 7.04 (pseudo-dt,
J=7.0, 1.0 Hz, 2H), 6.81 (s, 4H), 6.64 (s, 1H), 3.94 (s, 12H). 19F NMR
(DMSO-d6, 470 MHz): δ @61.31 (s, 6F), @137.74 (s, 11B@F). 13C NMR
(DMSO-d6, 125 MHz): δ 180.3, 165.7, 161.7, 155.9, 146.3, 142.5,
136.6, 135.9, 132.6, 131.1, 130.7 (q, J=31.4 Hz), 124.0 (q, J=
271.8 Hz), 124.1, 122.8, 120.0, 119.2 (q, J=4.0 Hz), 116.9 (q, J=
2.9 Hz), 116.7, 113.8, 109.7, 103.7, 99.8, 57.1. IR (cm@1): 3331, 2947–
2845, 1695, 1599, 1530, 1454, 1335, 1304, 1254, 1223, 1123, 1057.
bis-Flufenamic acid/CUR-BF2 Adduct (3): Yield 32%, orange solid,
mp 224–226 °C, Rf 0.62 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 9.36 (s, NH), 8.35 (dd, J=8.2 and 2.0 Hz, 2H), 8.12 (dd,
J=1.5 and 16.0 Hz, 2H), 7.84 (dd, J=3.0 and 9.5 Hz, 2H), 7.63–7.53
(m, 8H), 7.55 (d, J=5 Hz, 1H), 7.52 (d, J=5 Hz, 1H), 7.47–7.41 (m,
6H), 7.29 (d, J=16.0 Hz, 2H), 7.04 @7.01 (m, 2H), 6.54 (s, 1H). 19F
NMR (acetone-d6, 470 MHz): δ @63.31 (s, 6F), @116.92 (m, 2F),
@139.53 (s, 11B@F), @139.46 (s, 10B@F). 13C NMR (acetone-d6,
125 MHz): δ 180.8, 166.3, 160.4 (d, JCF=244 Hz), 147.5, 146.5 (d,
JCF=2.8 Hz), 141.4, 138.5 (d, JCF=1.9 Hz), 135.7, 132.2, 131.3 (q, JCF=
31.5 Hz), 130.4, 129.1 (d, JCF=8.7 Hz), 125.3 (q, JCF=271.8 Hz), 125.9
(d, JCF=8.5 Hz), 125.2, 124.7, 119.8 (q, JCF=3.9 Hz), 119.4 (d, J=
23.8 Hz), 118.9, 118.1 (JCF=3.8 Hz), 114.7, 114.1 (d, JCF=24.9 Hz),
111.4, 103.5. IR (cm@1): 2359, 1715, 1620, 1585, 1541, 1541, 1520,
1491, 1456, 1418, 1337, 1258, 1221, 1163, 1123, 1042.
bis-Flufenamic acid/CUR-BF2 Adduct (4): Yield 96.8%, orange solid,
mp 199 °C, Rf 0.86 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 9.42 (s, 2H), 8.27 (dd, J=8.3 Hz and 2.0 Hz, 2H), 8.12 (d,
J=16.0 Hz, 2H), 7.73 (d, J=2.0 Hz, 2H), 7.64–7.57 (m, 10H), 7.46–
7.42 (m, 6H), 7.23 (d, J=15.5 Hz, 2H), 7.02 (t, J=7.5 Hz, 2H), 6.59 (s,
1H), 3.97 (s, 6H). 19F NMR (acetone-d6, 470 MHz): δ @63.32 (6F),
@140.23 (s, 10B@F), @140.29 (s, 11B@F). 13C NMR (acetone-d6,
125 MHz): δ 180.6, 165.7 152.1, 147.1, 146.1, 142.7, 141.7, 135.3,
133.5, 132.2, 131.3 (q, JCF=32.4 Hz), 130.4, 124.5 (q, JCF=271.8 Hz),
124.0, 122.5, 121.7, 119.9 (distorted-q, JCF=3 Hz), 118.8, 114.7,
112.9, 112.1, 102.1, 55.7.
bis-Flufenamic acid/CUR Adduct (15): Yield 57.5%, yellow solid,
mp 107 °C, Rf (40% EtOAc in hexane). 1H NMR (CDCl3, 500 MHz):
9.50 (s, 2H), 8.28 (dd, J=8.3 Hz and 1.5 Hz, 2H), 7.69 (d, J=15.5 Hz,
2H), 7.51–7.32 (unresolved m, 12H), 7.26–7.21 (m, 6H), 6.92 (dt, J=
8.0 Hz and 1.0 Hz, 2H), 6.63 (d, J=16.0 Hz, 2H), 5.91 (s, 1H), 3.91 (s,
6H). 19F NMR (CDCl3, 470 MHz): δ @62.85 (CF3).13C NMR (CDCl3,
125 MHz): δ 183.1, 166.5, 151.7, 147.5, 141.3, 141.2, 140.0, 135.2,
134.2, 132.5, 131.9 (q, JCF=32.4 Hz), 130.0, 124.7, 124.4, 123.6, 123.9
(q, JCF=272.7 Hz), 121.2, 119.9 (q, J=3.8 Hz), 118.4, 118.2 (q, 3.9 Hz),
114.2, 111.6, 101.9, 56.1. HRMS (ESI): m/z [M+H]+ calcd for
C49H37F6N2O8: 895.245411; found: 895.1868. IR (cm
@1): 3331, 3074–
2841, 1699, 1632, 1582, 1506, 1454, 1416, 1333, 1252, 1227, 1200,
1161, 1119, 1045.
mono-Flufenamic acid/CUR-BF2 Adduct (5): Yield 67.8%, red solid,
mp 170 °C, Rf 0.20 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 9.42 (s, NH), 8.64 (s, 1H), 8.27 (dd, J=8.5 Hz and 1.5 Hz,
1H), 8.05 (d, J=15.0, 1H), 8.03 (d, J=16.0, 1H), 7.69 (d, J=2.0, 1H),
7.64–7.53 (m, 6H), 7.46–7.40 (m, 4H), 7.16 (d, J=15.5, 1H), 7.03–6.97
(m, 3H), 6.47 (s, 1H), 3.97 (s, 3H), 3.96 (s, 3H). 19F NMR (acetone-d6,
470 MHz): δ @63.32 (CF3), @140.70 (s, 10B@F), @140.76 (s, 11B@F). 13C
NMR (acetone-d6, 125 MHz): δ 181.2, 178.9, 165.7, 152.1, 151.4,
148.1, 147.0, 144.7, 142.4, 141.7, 135.2, 133.7, 132.3, 131.3 (q, JCF=
32 Hz), 130.4, 126.6., 125.3, 124.8, 124.7, 123.9 (q, JCF=271.0 Hz),
122.2, 121.9, 119.5 (q, JCF=3.7 Hz), 118.8, 118.0, 117.7 (q, JCF=
4.7 Hz), 115.7, 114.7, 112.7, 112.1, 111.9, 101.6, 55.7, 55.5.
mono-Flufenamic acid/CUR Adduct (16): Yield 29.5%, yellow solid,
mp 133 °C, Rf 0.53 (40% EtOAc in hexane). 1H NMR (CDCl3,
500 MHz): δ 9.48 (s, 1H), 8.27 (dd, J=8.0 Hz and 1.0 Hz, 1H), 7.64 (d,
J=15.5 Hz, 1H), 7.62 (d, J=15.5 Hz, 1H), 7.49–7.30 (m, 6H), 7.24–






























































J=8.0 Hz, 1H), 6.91 (t, J=6.5 Hz, 1H), 6.59 (d, J=16.0 Hz, 1H), 6.50
(d, J=16.0 Hz, 1H), 5.89 (br s, 1H), 5.85 (s, 1H), 5.30 (s, 1H), 3.95 (s,
3H), 3.89 (s, 3H).19F NMR (CDCl3, 470 MHz): δ @62.85 (CF3). 13C NMR
(CDCl3, 125 MHz): δ 184.6, 181.8, 166.5, 151.7, 148.0, 147.5, 146.8,
141.3, 141.2, 141.0,139.4, 135.2, 134.3, 132.5, 131.9 (q, JCF=32.4 Hz),
130.0, 127.6, 124.7, 124.4, 123.9 (q, JCF=272.7 Hz), 123.5, 123.1,
121.8, 121.0, 119.9 (q, JCF=3.8 Hz), 118.4, 118.2 (q, J=3.8 Hz), 114.9,
114.2, 111.6, 111.5, 109.7, 101.6, 56.0, 55.9. HRMS (ESI): m/z [M+H]+
calcd for C35H29O7F3N: 632.1896; found: 632.2006. IR (cm
@1): 3331,
3069–2841, 1699, 1628, 1582, 1506, 1454, 1429, 1416, 1333, 1254,
1202, 1161, 1121, 1034.
bis-Flurbiprofen/CUR-BF2 Adduct (6): Yield 63%, Dark orange solid,
mp: 230–232 °C, Rf 0.36 (40% EtOAc in hexane). 1H NMR (acetone-
d6, 500 MHz): δ 8.02 (d, J=15.5 Hz, 2H), 7.63–7.37 (complex region,
16H), 7.26 (s, 4H), 7.17 (d, J=15.5 Hz, 2H), 6.50 (s, 1H), 4.22 (q, J=
7.0 Hz, 2H), 3.88 (s, 12H), 1.65 (d, J=7.5 Hz, 6H). 19F NMR (acetone-
d6, 470 MHz): δ @119.5 (t, J=11.8 Hz, 2F), @140.2 (s, 10B@F), @140.3
(s, 11B@F). 13C NMR (acetone-d6, 125 MHz): δ 180.6, 170.9, 159.5 (d,
JCF=246.0 Hz), 152.8, 146.5, 142.3 (JCF=8.5 Hz), 135.5, 132.7, 131.8,
130.7 (d, J=4.0 Hz), 128.8, 128.5, 127.7, 127.6 (JCF=13.0 Hz), 124.3
d, J=3.7 Hz), 121.7, 115.4 (J=24.0 Hz), 106.2, 102.0, 55.8, 44.4, 18.3.
IR (cm@1): 2359, 1759, 1622, 1593, 1558, 1501, 1456, 1420, 1342,
1254, 1132, 1065, 1011.
bis-Flurbiprofen/CUR-BF2 Adduct (7): Yield 73.6%, orange solid,
mp 198 °C, Rf 0.39 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 8.05 (d, J=15.5 Hz, 2H), 7.62–7.37 (complex region,
20H), 7.20 (d, J=8.5 Hz, 2H), 7.15 (d, J=16.0 Hz, 2H), 6.53 (s, 1H),
4.22 (q, J=7.0 Hz, 2H), 3.89 (s, 6H), 1.66 (d, J=7.0 Hz, 6H). 19F NMR
(acetone-d6, 470 MHz): δ @119.33 (2F), @140.22 (s, 10B@F), @140.28
(s, 11B@F).13C NMR (acetone-d6, 125 MHz): δ 180.6, 171.3, 160.5,
158.6, 151.9, 146.1, 143.0, 142.2 (d, JCF=8.6 Hz), 135.5, 133.4, 130.8
(d, JCF=3.9 Hz), 128.9 (d, JCF=3.8 Hz), 128.5, 127.7, 127.6, 124.2 (d,
JCF=2.9 Hz), 123.4, 123.1 (q, JCF=245.0 Hz), 122.5, 121.6, 115.4 (d,
JCF=23.9 Hz), 112.9, 102.0, 55.5, 44.5, 18.2.
bis-Flurbiprofen/CUR Adduct (17): Yield 24%, yellow solid, mp
131 °C, Rf 0.84 (40% EtOAc in hexane). 1H NMR (CDCl3, 500 MHz): δ
7.69 (d, J=16.0 Hz, 2H), 7.59–7.57 (m, 4H), 7.48–7.46 (m, 6H), 7.46–
7.37 (m, 2H), 7.29 (unresolved d, 4H), 7.15 (dd, J=8.5 Hz and 1.5 Hz,
2H), 7.10 (d, J=2.0 Hz, 2H), 7.03 (d, J=8.0 Hz, 2H), 6.56 (d, J=
15.5 Hz, 2H), 5.86 (s, 1H), 4.07 (q, J=7.5 Hz, 2H), 3.81 (s, 6H), 1.68 (d,
J=7.5 Hz, 6H). 19F NMR (CDCl3, 470 MHz): δ @117.6 (pseudo-t). 13C
NMR (CDCl3, 125 MHz): δ 183.1, 171.8, 160.7, 158.7, 151.4, 141.4,
141.3 (d, JCF=7.7 Hz), 139.9, 135.5, 134.0, 130.8 (d, JCF=3.9 Hz),
129.0 (d, JCF=2.9 Hz), 128.0 (d, JCF=7.5 Hz), 127.7, 124.3, 123.8 (d,
JCF=2.9 Hz), 123.1, 121.1, 115.5 (d, JCF=24.0 Hz), 111.4, 101.8, 55.8,
44.9, 18.6. HRMS (ESI): m/z [M@H]@ calcd for C51H41F2O8: 819.276951;
found: 819.2860. IR (cm@1): 3059–2938, 1759, 1628, 1599, 1506,
1483, 1418, 1300, 1254, 1121, 1072, 1034.
mono-Flurbiprofen/CUR-BF2 Adduct (8): Yield 62.9%, dark-red
solid, mp 227 °C, Rf 0.15 (40% EtOAc in hexane). 1H NMR (acetone-
d6, 500 MHz): δ 8.63 (s, 1H), 8.04 (d, J=15.5 Hz, 1H), 7.97 (d, J=
15.5 Hz, 1H), 7.63–7.57 (m, 4H)), 7.51–7.49 (m, 3H), 7.54–7.36 (m,
5H), 7.18 (d, J=7.5 Hz, 1H), 7.11 (d, J=16.0 Hz, 1H), 6.98 (d, J=
15.5 Hz, 1H), 6.97 (d, J=8.5 Hz, 1H), 6.45 (s, 1H), 4.22 (q, J=7.5 Hz,
1H), 3.96 (s, 3H), 3.89 (s, 3H), 1.66 (d, J=6.5 Hz, 3H). 19F NMR
(acetone-d6, 470 MHz): δ @119.34 (pseudo-t, 1F), @140.68 (s, 10B@F),
@140.74 (s, 11B@F). 13C NMR (acetone-d6, 125 MHz): δ 181.2, 179.0,
171.3, 160.7, 158.7, 151.9, 151.4, 151.2, 148.0 (d, JCF=6.6 Hz), 144.7,
142.7, 142.2 (d, JCF=8.5 Hz), 135.5, 133.6, 130.8 (d, JCF=4.7 Hz),
128.9 (d, JCF=2.7 Hz), 128.5, 127.7 (d, JCF=3.0 Hz), 126.6, 125.3,
124.2 (d, JCF=2.8 Hz), 123.3, 122.2, 121.8, 117.9, 115.6, 115.4 (d,
JCF=24.7 Hz), 112.7, 111.8, 101.6, 55.5, 44.5, 18.2.
mono-Flurbiprofen/CUR Adduct (18): Yield 17.2%, orange solid,
mp 92 °C, Rf 0.58 (40% EtOAc in hexane). 1H NMR (CDCl3, 500 MHz):
7.62 (d, J=16.0 Hz, 1H), 7.60 (d, J=15.0 Hz, 1H), 7.58 (d, J=8.5 Hz,
2H), 7.48–7.45 (m, 3H), 7.39 (pseudo-tt, 1H), 7.37 (d and s
overlapping, 3H), 7.16–7.14 (m, 2H), 7.08 (dd, J=15.7 Hz and 1.5 Hz,
2H), 7.03 (d, J=8.5 Hz, 1H), 6.95 (d, J=8.0 Hz, 1H), 6.55 (d, J=
16.0 Hz, 1H), 6.50 (d, J=15.5 Hz, 1H), 5.84 (s, 1H), 4.06 (q, J=7.5 Hz,
1H), 3.96 (s, 3H), 3.81 (s, 3H), 1.68 (d, J=7.5 Hz, 3H). 19F NMR (CDCl3,
470 MHz): δ @117.7 (pseudo t). 13C NMR (CDCl3, 125 MHz): δ 184.5,
181.8, 171.9, 160.7, 158.7, 151.4, 148.0, 146.8, 141.3 (d, JCF=7.7 Hz),
141.3, 141.1, 139.4, 135.5, 134.2, 130.8 (d, JCF=3.8 Hz), 129.0 (d,
JCF=2.9 Hz), 128.5, 128.0 (d, JCF=13.3 Hz), 127.7, 127.6, 124.3, 123.8
(d, JCF=2.9 Hz), 123.0 (d, JCF=2.8 Hz), 121.8, 120.9, 115.5 (d, JCF=
23.7 Hz), 111.4, 109.7, 101.5, 56.0, 55.8, 44.9, 18.6. HRMS (ESI): m/z
[M@H]@ calcd for C36H30FO7: 593.19756; found: 593.1715. IR (cm@1):
3524, 3416, 3061–2841, 1757, 1626, 1587, 1506, 1450, 1418, 1296,
1267, 1204, 1121, 1072, 1032.
bis-Naproxen/CUR-BF2 Adduct (9): Yield 75.5%, dark red solid, mp
167 °C, Rf 0.30 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 8.03 (d, J=16.0 Hz, 2H), 7.88 (d, J=1.5 Hz, 2H), 7.86 (s,
2H), 7.84 (d, J=1.5 Hz, 2H), 7.58–7.55 (partially overlapping
doublets, J=2.0 Hz, 4H), 7.44 (dd, J=8.5 Hz and 2.0 Hz, 2H), 7.33 (d,
J=2.5 Hz, 2H), 7.18 (dd, J=9.0 Hz and 3.0 Hz, 2H), 7.13 (d, J=
15.5 Hz, 2H), 7.12 (d, J=7.5 Hz, 2H), 6.52 (s, 1H), 4.24 (q, J=7.0 Hz,
2H), 3.94 (s, 6H), 3.83 (s, 6H), 1.67 (d, J=6.5 Hz, 6H). 19F NMR
(acetone-d6, 470 MHz): δ @140.28 (s, 10B@F), @140.34 (s, 11B@F).13C
NMR (acetone-d6, 125 MHz): δ 188.4, 171.6, 157.7, 151.8, 145.8,
142.9, 135.5, 133.8, 133.0, 129.0, 128.8, 126.9, 126.2, 126.0, 123.2,
122.3, 121.3, 118.7, 112.6, 105.4, 101.8, 65.0, 55.3, 54.5, 18.1, 14.5.
bis-Naproxen/CUR Adduct (19): Yield 20%, yellow solid, mp 179 °C,
Rf 0.49 (40% EtOAc in hexane). 1H NMR (CDCl3, 500 MHz): δ 7.80 (s,
2H), 7.56 (pseudo-t, J=7.5 Hz, 4H), 7.59 (d, J=16.0 Hz, 2H), 7.53 (dd,
J=8.7 Hz and 2.0 Hz, 2H), 7.18–7.15 (m, 4H), 7.11 (dd, J=8.25 Hz
and 2.0 Hz, 2H), 7.06 (d J=1.5 Hz, 2H), 6.96 (d, J=8.5 Hz, 2H), 6.53
(d, J=7.5 Hz, 2H), 5.83 (s, 1H), 4.16 (q, J=7.5 Hz, 2H), 3.94 (s, 6H),
3.72 (s, 6H), 1.71 (d, J=7.0 Hz, 6H). 13C NMR (CDCl3, 125 MHz): δ
183.1, 172.5, 157.7, 151.5, 141.6, 140.0, 135.1, 133.9, 129.3, 129.0,
127.1, 126.4, 126.3, 124.2, 123.1, 121.0, 119.0, 111.5, 105.6, 101.7,
55.8, 55.3, 45.3, 18.7. HRMS (ESI): m/z [M+H]+ calcd for C49H45O10:
793.301275; found: 793.2805. IR (cm@1): 2934, 1755, 1630, 1605,
1506, 1452, 1416, 1300, 1265, 1121, 1070, 1032.
mono-Naproxen/CUR-BF2 Adduct (10): Yield 83.0%, maroon solid,
mp 151 °C, Rf 0.12 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 8.64 (s, 1H), 8.03 (d, J=16.0 Hz, 1H), 7.95 (d, J=15.5 Hz,
1H), 7.88 (d, J=1.5 Hz, 1H), 7.86 (s, 1H), 7.85 (d, J=1.5 Hz, 1H), 7.57
(dd, J=8.5 Hz and 2.0 Hz, 1H), 7.55 (d, J=2.0 Hz, 1H), 7.51 (d, J=
2.0 Hz, 1H), 7.42–7.39 (m, 2H), 7.33 (d, J=2.5 Hz, 1H), 7.18 (dd, J=
9.0 Hz and 2.5 Hz, 1H), 7.11 (d, J=8.0 Hz, 1H), 7.08 (d, J=15.5 Hz,
1H), 6.98 (d, J=15.0 Hz, 1H), 6.96 (d, J=8.5 Hz, 1H), 6.44 (s, 1H), 4.23
(q, J=6.5 Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.82 (s, 3H), 1.67 (d, J=
7.5 Hz, 3H). 19F NMR (acetone-d6, 470 MHz): δ @140.67 (s, 10B@F),
@140.74 (s, 11B@F). 13C NMR (acetone-d6, 125 MHz): δ 181.2, 179.0,
171.9, 158.0, 151.9, 148.1, 148.0, 144.7, 142.9, 135.5, 134.0, 133.4,
129.2, 129.0, 127.1, 126.6, 126.4, 126.1, 125.2, 123.3, 123.3, 122.1,
121.7, 118.9, 118.9, 115.7, 112.7, 111.9, 105.6, 101.5, 55.5, 55.4, 45.0,
18.3.
mono-Naproxen/CUR Adduct (20): Yield 30%, yellow solid, mp
148 °C, Rf 0.34 (40% EtOAc in hexane). 1H NMR (CDCl3, 500 MHz): δ
7.80 (s, 1H), 7.75 (pseudo-t, 8.5 Hz, 2H), 7.60 (d, J=16.0, 1H), 7.57 (d,
J=14.5, 1H), 7.53 (dd, J=8.5 Hz and 2.0 Hz, 1H), 7.18–7.19 (over-
lapping set of doublets, 4H), 7.06–7.01 (overlapping doublets, 2H),
6.96 (d, J=9.0 Hz, 1H), 6.94 (d, J=8.0 Hz, 1H), 6.52 (d, J=16.0 Hz,
1H), 6.49 (d, J=15.5 Hz, 1H), 5.87 (s, 1H), 5.82 (s, 1H), 4.15 (q, J=7.5,






























































125 MHz): δ 184.4, 181.9, 172.5, 157.7, 151.5, 148.0, 146.8, 141.5,
141.1, 139.5, 135.2, 134.0, 133.8, 129.3, 129.0, 127.6, 127.1, 126.4,
126.3, 124.2, 123.1, 123.0, 121.8, 120.9, 119.0, 114.8, 111.5, 109.6,
105.6, 101.5, 55.9, 55.8, 55.3, 45.3, 18.7. HRMS (ESI): m/z [M+H]+
calcd for C35H33O8: 581.2175; found: 581.2328. IR (cm
@1): 3524, 3408,
3003–2839, 1755, 1628, 1601, 1508, 1462, 1267, 1123, 1032.
bis-Indomethacin/CUR-BF2 Adduct (11) : Yield 54%, dark-red solid,
mp 168–170 °C, Rf 0.27 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 8.01 (d, J=16.0 Hz, 2H), 7.77 (d, J=8.0 Hz, 4H), 7.65 (d,
J=8.5 Hz, 4H), 7.26 (s, 4H), 7.21 (d, J=2.5 Hz, 2H), 7.17 (d, J=
15.5 Hz, 2H), 7.01 (d, J=9.0 Hz, 2H), 6.75 (dd, J=3.0 Hz and 9.2 Hz,
2H), 6.51 (s, 1H), 4.07 (s, 4H), 3.87 (s, 12H), 3.86 (s, 6H), 2.41 (s, 6H).
19F NMR (acetone-d6, 470 MHz): δ @140.26 (s, 10B@F), @140.32 (s,
11B@F). 13C NMR (acetone-d6, 125 MHz): δ 180.6, 168.1, 156.2, 152.8,
146.5, 138.4, 136.0, 134.6, 132.7, 132.0, 131.3, 130.9, 129.1, 121.7,
114.7, 112.5, 111.3, 106.3, 101.9, 55.9, 55.1, 12.7. IR (cm@1): 2916,
2848, 1763, 1684, 1616, 1593, 1541, 1503, 1458, 1342, 1260, 1130.
bis-Ibuprofen/CUR-BF2 Adduct (12)Yield 68%, orange solid, mp:
239–240 °C, Rf 0.64 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 7.97 (d, J=15.5 Hz, 2H), 7.38 (d, J=8.0 Hz, 4H), 7.21 (d,
J=7.0 Hz, 4H), 7.20 (s, 4H), 7.12 (d, J=15.5 Hz, 2H), 6.47 (s, 1H), 4.07
(q, J=7.5 Hz, 2H), 3.82 (s, 12H), 2.50 (d, J=7.5 Hz, 4H), 1.90 (septet,
J=6.5 Hz, 2H), 1.58 (d, J=7.5 Hz, 6H), 0.92 (d, J=6.0 Hz, 12H). 19F
NMR (acetone-d6, 470 MHz): δ @140.08 (s, 10B@F), @140.74 (s, 11B@F).
13C NMR (acetone-d6, 125 MHz): δ 180.5, 171.5, 152.9, 146.6, 140.3,
137.8, 132.6, 132.1, 129.1, 127.5, 121.5, 106.3, 102.0, 55.7, 44.7, 44.6,
30.1, 21.7, 18.6. IR (cm@1): 2953,1749, 1618, 1595, 1531, 1504, 1456,
1425, 1383, 1341, 1308, 1258, 1130, 1063, 1015.
mono-Ibuprofen/CUR-BF2 Adduct (13): Yield 81%, red solid, mp:
120 °C, Rf 0.33 (40% EtOAc in hexane). 1H NMR (acetone-d6,
500 MHz): δ 8.96 (s, 1H), 8.04 (d, J=16.0 Hz, 1H), 7.95 (d, J=16.0 Hz,
1H), 7.55 (d, J=2.0 Hz, 1H), 7.51 (d, J=2.0 Hz, 1H), 7.41 (pseudo-dt,
J=5.0 Hz and 2.0 Hz, 2H), 7.37 (distorted d, J=8.0 Hz, 2H), 7.21 (d,
J=8.0 Hz, 2H), 7.10 (d, J=8.0 Hz, 1H), 7.08 (d, J=15.5 Hz, 1H), 6.97
(d, J=15.0 Hz, 1H), 6.96 (d, J=8.5 Hz, 1H), 6.44 (s, 1H), 4.06 (q, J=
6.5 Hz,1H), 3.96 (s, 3H), 3.84 (s, 3H), 2.50 (d, J=7.5 Hz, 2H), 1.89
(sept, J=6.5 Hz, 1H), 1.58 (d, 7.5 Hz, 3H), 0.92 (d, J=6.5 Hz, 6H). 19F
NMR (acetone-d6, 470 MHz): δ @140.66 (s, 10B@F), @140.71 (s, 11B@F).
13C NMR (acetone-d6, 125 MHz): δ 181.1, 179.0, 172.0, 152.0, 148.1,
148.0, 144.7, 142.8, 140.4, 137.7, 133.4, 129.2, 127.4, 126.6, 125.3,
123.3, 122.2, 121.7, 121.5, 118.0, 115.7, 112.7, 111.8, 101.5, 55.5,
55.4, 44.6, 30.0, 21.73, 21.71, 18.4.
mono-Ibuprofen/CUR Adduct (21): Yield 29%, yellow solid, mp
100 °C, Rf 0.62 (40% EtOAc in hexane). 1H NMR (CDCl3, 500 MHz): δ
7.61 (d, J=16.0 Hz, 1H), 7.58 (d, J=16 Hz, 1H), 7.33 (d, J=8.0 Hz,
2H), 7.27 (d, J=2.0 Hz, 1H), 7.16–7.11 (overlapping doublets, 4H),
7.07 (d, J=6.5 Hz, 2H), 6.97 (d, J=8.0 Hz, 1H), 6.94 (d, J=8.0 Hz,
1H), 6.53 (d, J=15.5 Hz, 1H), 6.49 (d, J=16.0 Hz, 1H), 5.87 (s, 1H),
5.82 (s, 1H), 3.99 (q, J=6.5 Hz, 1H), 3.95 (s, 3H), 3.76 (s, 3H), 2.49 (d,
J=7.5 Hz, 2H), 1.88 (sept, J=6.5 Hz, 1H), 1.63 (d, J=7.5 Hz, 3H),
0.92 (d, J=6.5 Hz, 6H). 13C NMR (CDCl3, 125 MHz): δ 184.4, 181.9,
172.6, 151.5, 147.9, 146.8, 141.5, 141.0, 140.7, 139.5, 137.2, 134.0,
129.3, 127.6, 127.4, 124.1, 123.1, 123.0, 121.8, 121.0, 114.8, 111.5,
109.6, 101.5, 55.9, 55.8, 45.1, 30.2, 22.39, 22.38, 18.6. HRMS (ESI):
m/z [M@H]@ calcd for C34H35O7: 555.2382; found: 555.2431
3,5-Dimethoxybenzaldehyde/4-Flufenamic Adduct: Yield 72%,
white solid, mp 118 °C, Rf 0.65 (40% EtOAc in hexane). 1H NMR
(CDCl3, 500 MHz): δ 9.97 (s, 1H), 9.44 (s, 1H), 8.31 (dd, J=8.3 Hz and
1.0 Hz, 1H), 7.51–7.40 (m, 4H), 7.36 (d, J=8.0 Hz, 1H), 7.32 (d, J=
7.5 Hz, 1H), 7.23 (s, 2H), 6.92 (t, J=8.0 Hz, 1H), 3.93 (s, 6H). 19F NMR
(CDCl3, 470 MHz): δ @62.85. 13C NMR (CDCl3, 125 MHz): δ 191.0,
165.8, 153.2, 147.5, 141.2, 135.2, 134.6, 133.6, 131.9 (q, JCF=32.4 Hz),
130.0, 124.7, 123.9 (q, JCF=272.7 Hz), 119.8 (q, JCF=3.8 Hz), 118.5,
118.2 (q, JCF=7.7 Hz), 114.2, 111.4, 106.1, 56.5.. HRMS (ESI): m/z [M
+H]+ calcd for C23H19F3NO5: 446.1214; found: 446.1326.
2,6-Dimethoxybenzaldehyde/4-Flufenamic Adduct: Yield 37%,
white solid, mp 105 °C, Rf 0.57 (40% EtOAc in hexane). 1H NMR
(CDCl3, 500 MHz): δ 10.48 (s, 1H), 8.21 (dd, J=8.2 Hz and 1.5 Hz,
1H), 7.51–7.42 (m, 4H), 7.37–7.32 (m, 2H), 3.92 (s, 6H). 13C NMR
(CDCl3, 125 MHz): δ 188.2, 166.3, 163.2, 156.8, 148.0, 141.0, 135.6,
132.2, 132.0 (q, JCF=32.4 Hz), 130.1, 125.1, 123.9 (q, JCF=272.8 Hz),
120.3 (q, JCF=4.6 Hz), 118.6 (q, JCF=3.8 Hz), 118.4, 114.4, 112.4,
111.0, 98.4, 56.3. 19F NMR (CDCl3, 470 MHz): δ @62.84 (3F). HRMS
(ESI): m/z [M+H]+ calcd for C23H19F3NO5: 446.12153; found:
446.1058.
5-Fluorobenzaldehyde/2-Flufenamic Adduct: Yield 47%, light-
yellow solid, mp 96 °C, Rf 0.82 (40% EtOAc in hexane). 1H NMR
(CDCl3, 500 MHz): δ 10.19 (d, J=2.5 Hz, 1H), 9.34 (s, 1H), 8.27 (dd,
J=8.2 Hz and 2.0 Hz, 1H), 7.66 (dd, J=8.2 Hz and 3.0 Hz, 1H), 7.51–
7.46 (m, 3H), 7.43–7.39 (m, 2H), 7.36 (d, J=7.5 Hz, 1H), 7.35–7.31 (m,
2H), 6.93 (td, J=7.0 Hz and 1.0 Hz, 1H). 19F NMR (CDCl3, 470 MHz): δ
@62.84 (3F), @114.13 (q, J=9.9 Hz, 1F). 13C NMR (CDCl3, 125 MHz): δ
187.0, 166.8, 160.4 (d, JCF=248.0 Hz), 148.2, 148.1 (JCF=2.8 Hz),
140.8, 135.8, 132.2, 132.0 (q, JCF=32.4 Hz), 130.1, 129.8 (JCF=5.7 Hz),
123.8 (q, JCF=273.0 Hz), 125.5 (JCF=7.7 Hz), 125.3, 122.3 (JCF=
23.9 Hz), 120.4 (q, JCF=4.8 Hz), 118.8 (q, JCF=3.8 Hz), 118.5, 115.7
(JCF=24.0 Hz), 114.3, 110.4. HRMS (ESI): m/z [M+H]
+ calcd for
C21H14F4NO3: 404.09098; found: 404.0966.
3,5-Dimethoxybenzaldehyde/4-Flurbiprofen Adduct: Yield 37.3%
(141 mg), white solid, mp 115–116 °C, Rf 0.82 (40% EtOAc in
hexane). 1H NMR (CDCl3, 500 MHz): δ 9.91 (s, 1H), 7.58-7.56 (m, 2H),
7.48 – 7.44 (m, 3H), 7.39 (tt, J=7.5 Hz and 1.0 Hz, 1H), 7.32–7.28
(complex m, 2H), 4.13 (q, J=7.5 Hz, 1H), 3.85 (s, 6H), 1.69 (d, J=
7.0 Hz, 3H). 13C NMR (CDCl3, 125 MHz): δ 191.0, 171.2, 160.7, 158.7,
152.9, 141.4 (JCF=7.7 Hz), 135.5, 134.4, 133.8, 130.7 (JCF=3.8 Hz),
129.0 (JCF=2.8 Hz), 128.5, 128.0, 127.9, 127.7, 56.2, 44.8, 18.7.
19F
NMR (CDCl3, 470 MHz): δ @117.88 (pseudo-t, J=8.5 Hz). HRMS (ESI):
m/z [M+H]+ calcd for C24H22FO5: 409.14513; found: 409.1482.
3,5-Dimethoxybenzaldehyde/4-Naproxen Adduct: Yield 46%,
white solid, mp 69–71 °C, Rf 0.61 (40% EtOAc in hexane). 1H NMR
(CDCl3, 500 MHz): δ 9.87 (s, 1H), 7.83 (d, J=1 Hz, 1H), 7.75 (t, J=
8.5 Hz, 2H), 7.54 (dd, J=8.2 and 2.0 Hz, 1H), 7.18–7.16 (m, 2H), 7.09
(s, 2H), 4.22 (q, J=7.5 Hz, 1H), 3.93 (s, 3H), 3.75 (br s, 6H), 1.73 (d,
J=7.5 Hz, 3H). 13C NMR (CDCl3, 125 MHz): δ 191.1, 171.9, 157.7,
153.0, 135.2, 134.3, 134.1, 133.8, 129.3, 129.0, 126.9, 126.6, 126.3,
119.0, 106.1, 105.6, 56.2, 55.3, 45.2, 18.8. HRMS (ESI): m/z [M+H]+
calcd for C23H23O6: 395.149465; found: 395.1459.
2,6-Dimethoxybenzaldehyde/4-Naproxen Adduct: Yield 47%,
white solid, mp 140–141 °C, Rf 0.41 (40% EtOAc in hexane). 1H NMR
(CDCl3, 500 MHz): δ 10.39 (s, 1H), 7.78–7.73 (m, 3H), 7.49 (dd, J=
7.0 Hz and 1.5 Hz, 1H), 7.18 (dd, J=6.0 Hz and 2.5 Hz, 1H), 7.15 (d,
J=2.5 Hz, 1H), 6.26 (s, 2H), 4.09 (q, J=6.5 Hz, 1H), 3.93 (s, 3H), 3.82
(s, 6H), 1.71 (d, J=7.0 Hz, 3H). 13C NMR (CDCl3, 125 MHz): δ 188.2,
172.3, 163.1, 157.9, 157.0, 134.5, 133.9, 129.3, 129.0, 127.5, 126.2,
126.0, 119.3, 112.1, 105.6, 97.8, 56.2, 55.3, 45.7, 18.5. HRMS (ESI):
m/z [M+H]+ calcd for C23H23O6: 395.149465; found: 395.1400.
3,5-Dimethoxybenzaldehyde/4-Ibuprofen Adduct: Yield 60%,
white solid, mp 83 °C, Rf 0.63 (40% EtOAc in hexane). 1H NMR
(CDCl3, 500 MHz): δ 9.88 (s, 1H), 7.35 (d, J=8.0 Hz, 2H), 7.15 (d, J=
8.5 Hz, 2H), 7.10 (s, 2H), 4.05 (q, J=7.0 Hz, 1H), 3.78 (s, 6H), 2.48 (d,
J=6.5 Hz, 2H), 1.88 (septet, J=7.0 Hz, 1H), 1.64 (d, J=7.5 Hz, 3H),
1.22 (d, J=6.0 Hz), 0.92 (dd, J=6.5 Hz and 1.0 Hz, 6H). 13C NMR
(CDCl3, 125 MHz): δ 191.1, 171.9, 153.0, 140.6, 137.2, 134.2, 129.2,
127.5, 106.1, 56.2, 45.1, 44.9, 30.2, 25.4, 22.4, 18.7. HRMS (ESI): m/z






























































5-Fluorobenzaldehyde/2-Ibuprofen Adduct: Yield 13%, white
solid, mp 85 °C, Rf 0.86 (40% EtOAc in hexane). 1H NMR (CDCl3,
500 MHz): δ 9.68 (d, J=2.5 Hz, 1H), 7.53 (dd, J=8.2. and 3.5 Hz, 1H),
7.31–7.28 (m, 3H), 7.18 (d, J=8.0 Hz, 2H), 7.11 (dd, J=9.2 and
4.5 Hz, 1H), 4.04 (q, J=6.5 Hz, 1H), 2.49 (d, J=7.0 Hz, 2H), 1.88 (sept,
J=6.5 Hz, 1H), 1.66 (d, J=6.5 Hz, 3H), 0.92 (d, J=6.5 Hz, 6H). 13C
NMR (CDCl3, 125 MHz): δ 187.0, 172.9, 160.2 (J=247.9 Hz), 148.4
(J=2.8 Hz), 141.4, 136.5, 129.8, 129.4 (J=6.7 Hz), 127.2, 125.0 (J=
7.7 Hz), 122.1 (J=23.9 Hz), 115.0 (J=23.9 Hz), 45.2, 45.0, 30.2, 22.4,
18.0. 19F NMR (CDCl3, 470 MHz): δ @114.63 (m).
3,5-Dimethoxybenzaldehyde/4-Indomethacin Adduct: Yield 96%,
white solid, mp 149 °C, Rf 0.56 (40% EtOAc in hexane). 1H NMR
(CDCl3, 500 MHz): δ 7.67 (dt, J=6.5 Hz and 2.0 Hz, 2H), 7.46 (dt, J=
8.5 Hz and 2.5 Hz, 2H), 7.12 (s, 2H), 7.09 (d, J=2.5 Hz, 1H), 6.90 (d,
J=9.0 Hz, 1H), 6.69 (dd, J=9.2 Hz and 2.5 Hz, 1H), 3.98 (s, 2H), 3.84
(s, 3H), 3.81 (s, 6H), 2.44 (s, 3H). 13C NMR (CDCl3, 125 MHz): δ 191.0,
168.3, 168.1, 156.0, 152.9, 139.3, 136.3, 134.4, 133.9, 131.2, 130.9,
130.7, 129.1, 114.8, 112.2, 111.7, 111.4, 106.1, 101.9, 101.3, 56.3,
55.7, 29.7, 13.4. HRMS (ESI): m/z [M+H]+ calcd for C28H25ClNO7:
522.13195; found: 522.14.
4. Computational Methods
B3LYP/6-31G*[33] geometry optimizations were carried out with
the Gaussian 09 program.[34] Molecular docking calculations
were performed with the software AutoDock Vina (version
1.1.2)[35] for modeling the binding modes and assessing the
interaction energies of the studied compounds as ligands for
several enzymes. The three-dimensional coordinates of the
proteins were obtained from the RCSB Protein Data Bank (PDB
IDs: 3PP0[36] (HER2), 3SDK[37] (20S proteasome), 4AG8[38]
(VEGFR2), 4XV2[39] (BRAF), 4LVT[40] (Bcl-2), 4O1Z[41] (COX-1), and
4PH9[42] (COX-2)). Chain A of HER2, VEGFR2, BRAF, Bcl-2, COX-1
and COX-2, and chains K (β5 subunit) and L (β6 subunit) of 20S
proteasome were selected as target templates for the docking
computations. Co-crystallized ligands and crystallographic water
molecules were removed. Addition of hydrogens, merger of
nonpolar hydrogens to the atom to which they were linked,
and assignment of partial charges were computed with
AutoDockTools. Docking areas were constrained to a
30x30x30 Å box centered at the active site of the proteins,
providing proper space for rotational and translational move-
ment of the ligands. Octanol/water partition coefficients (LogP)
were evaluated by free Molinspiration molecular property
calculation service.[43]
5. Bioassay Methods
NCI-60 assay: samples were submitted to the National Cancer
Institute (NCI of NIH) Developmental Therapeutics anticancer
screening program (DTP) for human tumor cell line assay by
NCI-60 screening against leukemia, lung, colon, and CNS
cancers, as well as melanoma, ovarian, renal, prostate, and
breast cancers. Compounds are initially tested at a single dose
of 10@5 molar. Data are reported as mean graph of percent
growth (GP). Selected data output are shown in SI file. Growth
inhibition is represented by values between 0 and 100 and
lethality by values less than zero. Detailed procedures for the
one-dose and five-dose screening assays are reported here:
https://dtp.cancer.gov/discovery_development/nci-60/method-
ology.htm
6. Cell viability, Cytotoxicity and Apoptosis
Assay for Colorectal Cells
Colorectal cancer (HCT116, HT29, DLD-1, RKO, SW837 and
Caco2) and normal colon cell lines (CCD841CoN) were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA). Cells were maintained in DMEM medium (Life Technolo-
gies, Carlsbad, CA) supplemented with 10% fetal bovine serum
(Life Technologies), 1% non-essential amino acids (Life Tech-
nologies), 1% penicillin-streptomycin (Life Technologies), and
1% glutamine (Life Technologies) at 37 °C and 5% CO2. For the
assessment of cell viability, cells were seeded in 96-well plates
with approximately 5.0×103 cells / well and incubated in
RPMI1640 medium (supplemented with 10% fetal bovine serum
and 1% glutamine) for 24 hours. Cells were then treated with
DMEM medium containing CUR compounds (10 μM) or vehicle
(DMSO) for 72 hours and the number of viable cells was
determined using CellTiter-Glo® cell viability assay system
(Promega, Madison WI). After addition of the reagent (CytoTox-
GloTM or Caspase-Glo® 3/7 Assay System) to the cell culture
medium, luminescence was measured by infinite M200 Pro
microplate reader (TECAN).
7. Inflammation response (Figure S3)
Human macrophage cells (THP-1) was obtained from the ATCC
(Manassas, VA). Cells were maintained in DMEM medium
supplemented with 10% fetal bovine serum, 1% non-essential
amino acids, 1% penicillin-streptomycin, and 1% glutamine at
37 °C and 5% CO2. For the inflammation assay, cells were
seeded in T75 flask with approximately 9.0×105 cells / flask and
incubated in DMEM medium for 24 hours. Cells were treated for
2 hours with Lipopolysaccharide (LPS, Millipore-Sigma, St Louis,
MO) at a concentration of 100 ng/ml or vehicle control
(Phosphate-Buffered Saline (PBS, Life Technologies) to induce
an inflammatory state. After the incubation, culture media
containing LPS or PBS was removed and replaced for 24 hours
with DMEM media containing curcumin derivatives, the parent
compound at a concentration of 10 μM or vehicle control
(DMSO). Twenty-four hours after the treatment, cells were
rinsed by PBS, and total RNAs were isolated using Qiagen’s
RNeasy Micro Kit (Qiagen, Hilden, Germany) per the manufac-
turer’s instructions. Complimentary DNA (cDNA) was generated
using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). The mRNA levels of Interleukin 1β
(IL-1β) and β-actin (the structural housekeeping gene) were
measured using TaqMan Gene Expression Assay (Applied
Biosystems) and Quant-Studio 6 Quantitative Real-Time PCR






























































cycle threshold (Ct) values were used via the ΔΔCt method to
calculate fold change in gene expression.
8. Statistical analysis
All statistical analyses were performed using GraphPad Prism 7
software. A statistically significant difference was determined
using unpaired t-test with Welch’s correction. Data were
presented as mean � standard error of mean and was
considered statistically significant when p-value was <0.05.
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